- JP-listed companies
- Kohjin Bio Co., Ltd.
- Income statement
Kohjin Bio Co., Ltd. (177A) Income statement
Market cap
¥5.5B
P/E ratio
49.6x
Kojin Bio manufactures bacterial culture media, antigen test kits, and cell culture products for research institutions, pharmaceutical companies, and medical facilities.
| 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Revenue | 2,276 | 2,826 | 3,251 | 3,947 | 4,743 | 4,770 | 5,206 | 4,939 |
| Revenue growth (%) | - | |||||||
| Cost of revenue | - | - | - | 1,908 | 2,289 | 2,889 | 2,840 | 3,082 |
| Gross profit | - | - | - | 2,039 | 2,454 | 1,881 | 2,366 | 1,857 |
| Gross margin (%) | - | - | - | |||||
| Operating margin (%) | - | - | - | |||||
| Operating expenses | - | - | - | 1,070 | 1,187 | 1,284 | 1,375 | 1,516 |
| Operating income | - | - | - | 970 | 1,267 | 597 | 991 | 341 |
| Income before tax | 75 | 456 | 666 | 918 | 1,244 | 636 | 1,065 | 340 |
| Pretax margin (%) | 3.3 | 16.1 | 20.5 | 23.3 | 26.2 | 13.3 | 20.5 | 6.9 |
| Provision for income taxes | - | - | - | 334 | 415 | 251 | 221 | 81 |
| Effective tax rate (%) | - | - | - | |||||
| Net income | -102 | 303 | 685 | 588 | 830 | 385 | 795 | 62 |
| Earnings per share | -302.31 | 896.59 | 2,023.85 | 173.5 | 199.23 | 92.43 | 157.57 | 49.11 |
| Dividend per share | - | - | - | - | 19 | 14 | 24 | 10 |